Zymeworks BC Inc (NASDAQ: ZYME) is -16.55% lower on its value in year-to-date trading and has touched a low of $6.01 and a high of $13.14 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ZYME stock was last observed hovering at around $8.85 in the last trading session, with the day’s loss setting it -0.18%.
Currently trading at $8.67, the stock is -11.17% and -20.22% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.41 million and changing -2.03% at the moment leaves the stock -1.83% off its SMA200. ZYME registered -13.13% loss for a year compared to 6-month gain of 19.59%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -17.66% loss in the last 1 month and extending the period to 3 months gives it a -12.07%, and is -7.37% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.55% over the week and 4.09% over the month.
Zymeworks BC Inc (ZYME) has around 277 employees, a market worth around $617.48M and $76.01M in sales. Profit margin for the company is -156.13%. Distance from 52-week low is 44.14% and -34.02% from its 52-week high. The company has generated returns on investments over the last 12 months (-24.36%).
The EPS is expected to grow by 43.22% this year
The shares outstanding are 70.12M, and float is at 65.94M with Short Float at 7.63%.
Zymeworks BC Inc (ZYME) Insider Activity
The most recent transaction is an insider sale by Galbraith Kenneth, the company’s Chair & CEO. SEC filings show that Galbraith Kenneth sold 5,706 shares of the company’s common stock on Jan 08 ’24 at a price of $11.22 per share for a total of $63996.0. Following the sale, the insider now owns 23762.0 shares.
Zymeworks BC Inc disclosed in a document filed with the SEC on Jan 08 ’24 that Moore Paul Andrew (Chief Scientific Officer) sold a total of 2,339 shares of the company’s common stock. The trade occurred on Jan 08 ’24 and was made at $11.22 per share for $26233.0. Following the transaction, the insider now directly holds 7367.0 shares of the ZYME stock.
Still, SEC filings show that on Jan 08 ’24, Astle Christopher (SVP & Chief Financial Officer) disposed off 1,431 shares at an average price of $11.22 for $16050.0. The insider now directly holds 6,503 shares of Zymeworks BC Inc (ZYME).
